Skip to main content

Table 4 Adjusted odds ratios for FN in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively (Broad Definition of FN)

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

  Adjusted Odds Ratio for FN (95% CI, p-value)*
Cycle 1 Cycle 2 Cycles ≥3 Last Cycle All Cycles
Commercial
 Independent Variables
  No PEG Prophylaxis 2.6 (2.3–2.8, < 0.001) 1.9 (1.6–2.2, < 0.001) 1.5 (1.4–1.7, < 0.001) 1.5 (1.4–1.7, < 0.001) 2.1 (2.0–2.3, < 0.001)
  FN in Prior Cycle 3.2 (2.6–3.9, < 0.001) 3.5 (3.2–4.0, < 0.001) 2.4 (2.0–2.8, < 0.001) 2.4 (2.2–2.6, < 0.001)
  Regimen
   TAC 2.9 (2.6–3.3, < 0.001) 2.6 (1.7–4.1, < 0.001) 1.7 (1.4–1.9, < 0.001) 3.3 (2.4–4.8, < 0.001) 2.7 (2.2–3.2, < 0.001)
   TC
   TCH 1.1 (1.0–1.2, 0.229) 2.2 (1.4–3.3, < 0.001) 1.1 (1.0–1.2, 0.266) 2.1 (1.5–2.9, < 0.001) 1.4 (1.2–1.6, < 0.001)
   CHOP±R 1.3 (1.2–1.5, < 0.001) 4.1 (1.9–9.0, < 0.001) 1.7 (1.5–1.9, < 0.001) 4.3 (2.4–7.7, < 0.001) 2.6 (1.9–3.5, < 0.001)
  Age
   18–49
   50–64 1.0 (0.9–1.1, 0.377) 1.0 (0.9–1.2, 0.884) 1.1 (1.0–1.2, 0.242) 1.3 (1.1–1.4, 0.002) 1.0 (1.0–1.1, 0.409)
   65–74 1.3 (1.2–1.5, < 0.001) 1.0 (0.8–1.2, 0.881) 1.5 (1.3–1.8, < 0.001) 1.7 (1.4–2.1, < 0.001) 1.3 (1.2–1.4, < 0.001)
   ≥ 75 1.7 (1.4–2.1, < 0.001) 1.2 (0.9–1.7, 0.200) 2.1 (1.8–2.6, < 0.001) 3.4 (2.7–4.3, < 0.001) 1.7 (1.5–2.0, < 0.001)
Medicare
 Independent Variables
  No PEG Prophylaxis 1.6 (1.5–1.7, < 0.001) 1.6 (1.5–1.8, < 0.001) 1.3 (1.3–1.4, < 0.001) 1.0 (0.9–1.0, 0.507) 1.5 (1.4–1.5, < 0.001)
  FN in Prior Cycle 3.2 (2.9–3.5, < 0.001) 2.9 (2.7–3.1, < 0.001) 1.7 (1.6–1.8, < 0.001) 2.1 (2.1–2.2, < 0.001)
  Regimen
   TAC 2.5 (2.2–2.9, < 0.001) 1.9 (1.5–2.4, < 0.001) 2.0 (1.7–2.3, < 0.001) 2.2 (1.9–2.6, < 0.001) 2.1 (1.9–2.3, < 0.001)
   TC
   TCH 0.8 (0.7–0.9, < 0.001) 0.9 (0.8–1.0, 0.127) 0.8 (0.7–0.9, < 0.001) 1.0 (0.9–1.2, 0.387) 0.8 (0.7–0.8, < 0.001)
   CHOP±R 1.5 (1.4–1.5, < 0.001) 1.8 (1.7–2.0, < 0.001) 1.9 (1.8–2.0, < 0.001) 1.8 (1.7–2.0, < 0.001) 1.6 (1.6–1.7, < 0.001)
  Age
   65–74
   75–84 1.2 (1.1–1.3, < 0.001) 1.0 (0.9–1.1, 0.709) 1.1 (1.1–1.2, < 0.001) 1.2 (1.1–1.3, < 0.001) 1.1 (1.1–1.2, < 0.001)
   ≥ 85 1.4 (1.3–1.5, < 0.001) 1.2 (1.1–1.4, < 0.001) 1.4 (1.3–1.5, < 0.001) 1.8 (1.6–1.9, < 0.001) 1.4 (1.3–1.4, < 0.001)
  1. FN febrile neutropenia, PEG pegfilgrastim, TC docetaxel + cyclophosphamide, TAC docetaxel + doxorubicin + cyclophosphamide, TCH docetaxel + cyclophosphamide + trastuzumab, CHOP cyclophosphamide + doxorubicin + vincristine + prednisone, R, rituximab
  2. *Adjusted for other characteristics of patients listed in Table 1; additional covariates selected via backward selection method